REMEDIUM CAPITAL PARTNERS LLC
Q4 2025 Form 13-F

FORT LAUDERDALE, DELAWARE
CIK 0002104501 · CRD 340302 · SEC-registered investment adviser
$170.2M Reported Value Total

REMEDIUM CAPITAL PARTNERS reports 1 total accounts under management (AUM). There are 1 discretionary accounts valued at $155,000,000, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Source: Form ADV filed 2026-08-20
Reported value
$170.2M
Quarter over quarter
0.0%
Holdings
6
Top-10 concentration
100.0%

Key People

Form ADV owners & control persons
Chad Christopher Hellmann
CHIEF COMPLIANCE OFFICER

Filing Navigation

13F Metrics

Loading 13F Metrics

Q4 2025 13F record

Q4 2025 13F filing summary

Q4 2025 Form 13F portfolio summary
Period of report December 31, 2025
Filed February 12, 2026
Form 13F-HR
Reported value $170.2M
Positions 6
Change in reported value First reported quarter
Top-10 concentration 100.0%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 13, 2026
6 $273.6M
Q2 2026 13F
Filed Aug 7, 2026
6 $451.6M
Q1 2026 13F
Filed May 13, 2026
6 $281.2M
Q4 2025 13F
Filed Feb 12, 2026
6 $170.2M

Top 6 holdings · Q4 2025

Largest Q4 2025 13F positions by reported value
# Holding Reported value % of portfolio
1 SYRE Spyre Therapeutics Inc $47.7M 28.03%
2 ORKA Oruka Therapeutics Inc $47.1M 27.64%
3 APGE Apogee Therapeutics Inc $44.1M 25.88%
4 JBIO Jade Biosciences Inc $24.3M 14.3%
5 CBIO Crescent Biopharma Inc $4.3M 2.52%
6 GLTO Galecto Inc $2.8M 1.63%

Values as reported on the Q4 2025 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings